ArticleJCEM case reports2025
FSH-secreting Giant Pituitary Macroadenoma With Aggressive Clinical Behavior.
Article in JCEM case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We describe a case of a 51-year-old woman with a 15-year history of a functional gonadotroph adenoma (FGA) secreting FSH, characterized by persistent hormonal hypersecretion, progressive tumor growth despite multiple surgeries, and anterior hypopituitarism. She initially presented at age 35 with menorrhagia and diplopia and underwent transsphenoidal surgery (TSS) abroad. Upon relocating to the United States 3 years later, she presented with recurrent menorrhagia, elevated FSH and estradiol, and a 3.2 cm invasive macroadenoma, requiring repeat TSS. Pathology demonstrated isolated FSH immunopositivity with a low Ki-67 index (≤3%). The postoperative course was complicated by central hypothyroidism and adrenal insufficiency. Despite a trial of bromocriptine, she experienced ongoing menorrhagia and tumor growth to 6.8 cm, requiring a third TSS and hysterectomy. Management was further complicated by inconsistent follow-up and hesitancy toward recommended radiotherapy. Fifteen years after her initial presentation, the residual tumor exceeded 8 cm, causing seizures, hallucinations, and vision loss despite persistently low Ki-67 proliferation (<3%). This case highlights the diagnostic and therapeutic challenges of FGAs, especially when tumor behavior is discordant with low-grade histologic features. It underscores the need for improved prognostic markers and earlier consideration of multimodal therapy, including radiotherapy and chemotherapy, in refractory cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.